A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...

Assessment of PSMA PET/CT derived predictive markers for 177Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...

Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage tria ...

In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.

Four of 35 (11%; 95% CI, 3.2 to 26.7) HRP and four of 12 HRRm patients responded. Median PFS was 8.2 months (95% CI, 5.3 to not reached) for HRP patients. Thirty-six percent of patients had ≥grade 3 ...